<html xmlns="http://www.w3.org/1999/xhtml" xmlns="http://www.w3.org/1999/xhtml">
 <head xmlns="http://www.w3.org/1999/xhtml">
 <title xmlns="http://www.w3.org/1999/xhtml"></title>
 </head>
 <body xmlns="http://www.w3.org/1999/xhtml">
 
 ArQule, Inc. ARQL today announced that preclinical data for 
 ARQ 531 in diffuse large B-cell lymphoma (DLBCL) in vitro and in 
 vivo tumor models was presented at EHA Congress in Madrid, Spain. 
 ARQ 531 is an investigational, orally bioavailable, potent and 
 reversible inhibitor of both wild type and C481S-mutant Bruton's 
 tyrosine kinase (BTK).
 
 
 The presentation titled "ARQ 531, A Reversible BTK Inhibitor, 
 Demonstrates Potent Anti-Tumor Activity in ABC-DLBCL and GCB-DLBCL" can 
 be viewed at <a xmlns="http://www.w3.org/1999/xhtml" href="http://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.arqule.com%2Fwp-content%2Fuploads%2FARQ531_EHA_2017.pdf&amp;esheet=51579296&amp;newsitemid=20170623005026&amp;lan=en-US&amp;anchor=https%3A%2F%2Fwww.arqule.com%2Fwp-content%2Fuploads%2FARQ531_EHA_2017.pdf&amp;index=1&amp;md5=bc1ef1766e75dce40702b7e4e1d58e53" rel="nofollow" rel="nofollow">https://www.arqule.com/wp-content/uploads/ARQ531_EHA_2017.pdf</a>.
 
 
 ARQ 531 Poster Presentation Highlights
 
 <ul xmlns="http://www.w3.org/1999/xhtml">
 <li xmlns="http://www.w3.org/1999/xhtml" class="bwlistitemmargb">
 Preclinical data suggests ARQ 531 has the potential for broad clinical 
 utility in a wide range of hematological malignancies and lymphomas.
 </li>
 <li xmlns="http://www.w3.org/1999/xhtml" class="bwlistitemmargb">
 The signaling pathways evaluated show a distinct kinase inhibition 
 profile that could be advantageous in treating lymphomas.
 </li>
 <li xmlns="http://www.w3.org/1999/xhtml" class="bwlistitemmargb">
 ARQ 531, unlike other BTK inhibitors, has activity in both ABC-DLBCL 
 and GCB-DLBCL preclinical models.
 </li>
 <li xmlns="http://www.w3.org/1999/xhtml" class="bwlistitemmargb">
 A phase 1 trial with ARQ 531 in patients with B-cell malignancies 
 refractory to other therapeutic options, including ibrutinib, is 
 planned to commence by the third quarter of 2017.
 </li>
 </ul>
 
 &#34;This data further strengthens a very comprehensive preclinical package 
 for ARQ 531,&#34; said Dr. Brian Schwartz, M.D., Head of Research and 
 Development and Chief Medical Officer at ArQule. &#34;While targeting 
 ibrutinib resistant patients will be an initial, fast-to-market strategy 
 for the clinical development of ARQ 531, the data presented at EHA 
 clearly demonstrate the potential clinical utility of the drug beyond 
 ibrutinib refractory cancers.&#34;
 
 
 B-cell malignancies, like chronic lymphocytic leukemia, Waldenstrom's 
 macroglobulinemia, DLBCL and mantle cell lymphoma are driven by BTK. The 
 only approved BTK inhibitor, ibrutinib, is irreversible and makes a 
 covalent bond with the C481 residue of the targeted protein. Although 
 ibrutinib has demonstrated excellent responses in patients with elevated 
 B-cell receptor signaling, clinical resistance has been observed, and 
 the BTK C481S mutation is emerging as a predominant mechanism of 
 resistance. As a reversible inhibitor, ARQ 531 does not require 
 interaction with the C481 residue, a binding site essential for 
 irreversible ibrutinib binding to BTK, thus positioning ARQ 531 as a 
 targeted therapy for patients harboring C481S-mutant BTK who have 
 developed resistance to irreversible BTK inhibitors.
 
 
 About BTK and ARQ 531
 
 
 ARQ 531 is an investigational, orally bioavailable, potent and 
 reversible Bruton's tyrosine kinase (BTK) inhibitor. Biochemical and 
 cellular studies have shown that ARQ 531 inhibits both the wild type and 
 C481S-mutant forms of BTK. The C481S mutation is a known emerging 
 resistance mechanism for first generation irreversible BTK inhibitors. 
 In preclinical studies ARQ 531 has demonstrated high oral 
 bioavailability as well as good ADME, pharmacokinetic and metabolic 
 properties. The company plans to initiate a phase 1 trial by the third 
 quarter of 2017. BTK is a therapeutic target that has been clinically 
 proven to inhibit B-cell receptor signaling in blood cancers.
 
 
 About ArQule
 
 
 <a xmlns="http://www.w3.org/1999/xhtml" href="http://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.arqule.com&amp;esheet=51579296&amp;newsitemid=20170623005026&amp;lan=en-US&amp;anchor=ArQule&amp;index=2&amp;md5=b17462c93e23cd7f0937b40034ac2f79" rel="nofollow" rel="nofollow">ArQule</a> 
 is a biopharmaceutical company engaged in the research and development 
 of targeted therapeutics to treat cancers and rare diseases. ArQule's 
 mission is to discover, develop and commercialize novel small molecule 
 drugs in areas of high unmet need that will dramatically extend and 
 improve the lives of our patients. Our clinical-stage pipeline consists 
 of five drug candidates, all of which are in targeted, biomarker-defined 
 patient populations, making <a xmlns="http://www.w3.org/1999/xhtml" href="http://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.arqule.com&amp;esheet=51579296&amp;newsitemid=20170623005026&amp;lan=en-US&amp;anchor=ArQule&amp;index=3&amp;md5=b374d4719f682a93cb28cc11877c8f82" rel="nofollow" rel="nofollow">ArQule</a> 
 a leader among companies our size in precision medicine. ArQule's 
 proprietary pipeline includes: ARQ 087, a multi-kinase inhibitor 
 designed to preferentially inhibit the fibroblast growth factor receptor 
 (FGFR) family, in phase 2 for iCCA and in phase 1b for multiple oncology 
 indications; ARQ 092, a selective inhibitor of the AKT serine/threonine 
 kinase, in a phase 1/2 company sponsored study for Overgrowth Diseases, 
 in a phase 1 study for ultra-rare Proteus syndrome conducted by the 
 National Institutes of Health (NIH), as well as in multiple oncology 
 indications; ARQ 751, a next generation AKT inhibitor, in phase 1 for 
 patients with AKT1 and PI3K mutations; and ARQ 761, a β-lapachone analog 
 being evaluated as a promoter of NQO1-mediated programmed cancer cell 
 necrosis, in phase 1/2 in multiple oncology indications in partnership 
 with the University of Texas Southwestern Medical Center. In addition, 
 we have advanced ARQ 531, an investigational, orally bioavailable, 
 potent and reversible inhibitor of both wild type and C481S-mutant BTK, 
 through toxicology testing and plan to initiate a phase 1 trial by the 
 third quarter of 2017. ArQule's current discovery efforts are focused on 
 the identification and development of novel kinase inhibitors, 
 leveraging the Company's proprietary library of compounds. You can 
 follow us on <a xmlns="http://www.w3.org/1999/xhtml" href="http://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Ftwitter.com%2FArQuleInc&amp;esheet=51579296&amp;newsitemid=20170623005026&amp;lan=en-US&amp;anchor=Twitter&amp;index=4&amp;md5=eb886dd2aa3190cbebcefd7285bf45b1" rel="nofollow" rel="nofollow">Twitter</a> 
 and <a xmlns="http://www.w3.org/1999/xhtml" href="http://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Farqule&amp;esheet=51579296&amp;newsitemid=20170623005026&amp;lan=en-US&amp;anchor=LinkedIn&amp;index=5&amp;md5=59021e5ad0379000f5ec9eda36fbe8e7" rel="nofollow" rel="nofollow">LinkedIn</a>.
 
 
 Forward Looking Statements
 
 
 This press release contains forward-looking statements regarding 
 preclinical experiments and planned clinical trials with ARQ 531. These 
 statements are based on the Company's current beliefs and expectations, 
 and are subject to risks and uncertainties that could cause actual 
 results to differ materially. Positive information about 
 pre-clinical results does not ensure that clinical trials will be 
 successful. For example, ARQ 531 may not demonstrate promising 
 therapeutic effect in man; in addition, it may not exhibit an adequate 
 safety profile in planned or later stage or larger scale clinical trials 
 as a result of known or as yet unanticipated side effects. The results 
 achieved in later stage trials may not be sufficient to meet applicable 
 regulatory standards or to justify further development. Problems or 
 delays may arise during clinical trials or in the course of developing, 
 testing or manufacturing ARQ 531 that could lead the Company to 
 discontinue development. Even if later stage clinical trials are 
 successful, unexpected concerns may arise from subsequent analysis of 
 data or from additional data. Obstacles may arise or issues may be 
 identified in connection with review of clinical data with regulatory 
 authorities. Regulatory authorities may disagree with the Company's view 
 of the data or require additional data or information or additional 
 studies. Drug development involves a high degree of risk. Only a small 
 number of research and development programs result in the 
 commercialization of a product. For more detailed information on the 
 risks and uncertainties associated with the Company's drug development 
 and other activities, see the Company's periodic reports filed with the 
 Securities and Exchange Commission. The Company does not undertake any 
 obligation to publicly update any forward-looking statements.
 
 
 
 <img xmlns="http://www.w3.org/1999/xhtml" alt="" src="http://cts.businesswire.com/ct/CT?id=bwnews&amp;sty=20170623005026r1&amp;sid=benz2&amp;distro=nx&amp;lang=en"></img>View source version on businesswire.com: <a xmlns="http://www.w3.org/1999/xhtml" href="http://www.businesswire.com/news/home/20170623005026/en/" rel="nofollow" rel="nofollow">http://www.businesswire.com/news/home/20170623005026/en/</a></body></html>

Press Releases

ArQule Presents Preclinical Data for BTK Inhibitor, ARQ 531, at the 22nd Annual Congress of the European Hematology Association (EHA) 

ARQL

ArQule Presents Preclinical Data for BTK Inhibitor, ARQ 531, at the 22nd Annual Congress of the European Hematology Association (EHA)

KNTK


Kinetik Holdings Inc. (NYSE:KNTK) (&#34;Kinetik&#34; or the &#34;Company&#34;) has declared a cash dividend of $0.75 per share ($3.00 on an annualized basis) for the first quarter ended March 31, 2024. The announced quarterly dividend

Kinetik Announces First Quarter Dividend and Financial Results Timing


Turning Point Brands, Inc. (NYSE:TPB) announced the date and time for its conference call to review first quarter 2024 results. The conference call will be on Thursday, May 2nd, 2024, at 10:00 a.m. Eastern to discuss

Turning Point Brands to Host First Quarter 2024 Conference Call


Texas Pacific Land Corporation (NYSE:TPL) (the &#34;Company&#34;) announced today that the Company will release first quarter 2024 financial results after the market closes on Wednesday, May 8, 2024. A conference call will be

Texas Pacific Land Corporation Sets Dates for First Quarter 2024 Earnings Release and Conference Call

PKST


Peakstone Realty Trust (&#34;PKST&#34; or the &#34;Company&#34;) (NYSE:PKST), a real estate investment trust that owns and operates a high-quality, newer-vintage portfolio of predominantly single-tenant industrial and

Peakstone Realty Trust Announces Date for First Quarter 2024 Earnings Release and Webcast


Xylem Inc. (NYSE:XYL), a leading global water technology company dedicated to solving the world&#39;s most challenging water issues, today announced it will host its 2024 Investor Day on May 30, beginning at 11:00 a.m.

Xylem to Host Investor Day on May 30, 2024

KVYO


Klaviyo, Inc. (NYSE:KVYO), the company that powers smarter digital relationships, plans to announce its financial results for the first quarter of fiscal year 2024 after market close on Wednesday, May 8, 2024.


Klaviyo